Publikationsliste einschränken

Chart

 bis  

• englisch (30)

• Michaeli, Christoph T. (26)
• Michaeli, Julia (11)
• Boch, Tobias (5)
• Albers, Sebastian (3)
• Yard, Benito A. (1)
• Stach-Jablonski, Ksenija (1)
• Torre, Carolina de la (1)

• An, Liying (1)
• Schreiner, Yannick (1)
• Faust, Sara (1)
• Krämer, Bernhard (1)

• Kanavos, Panos (3)
• Yagmur, Hasan Basri (2)
• Achmadeev, Timur (2)
• Mills, Mackenzie (2)
• Miracolo, Aurelio (2)
• Jürges, Hendrik (1)
• Würstlein, Rachel (1)

• Dannehl, Dominik (1)
• Mills, Mackenzie (1)
• Zhang, Wenjia (1)
• Stoycheva, Sophia (1)
• Marcus, Simon Mashudu (1)
• Yagmur, Hasan (1)
• Trapani, Dario (1)

Publikationen in heiBIB     

• Michaeli, Daniel: Value-based indication-specific pricing and weighted-average pricing : estimated price and cost savings for cancer drugs / Daniel Tobias Michaeli, Thomas Michaeli, April 2025. - 13 S.
  In: PharmacoEconomics, ISSN 1179-2027. 43(2025), 4 vom: Apr., Seite 415-427
  DOI: 10.1007/s40273-024-01448-x
• Michaeli, Daniel: The healthcare workforce shortage of nurses and physicians : practice, theory, evidence, and ways forward / Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Thomas Michaeli. -
  Los Angeles: Sage, 2024. - 1 Online-Ressource (12 Seiten) : Diagramme
  DOI: 10.11588/heidok.00036055
• Michaeli, Daniel: Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention / vorgelegt von Daniel Tobias Michaeli ; Referent: Priv.-Doz. Dr. med. Tobias Boch. -
  Heidelberg, 2024. - 98 Blätter : Illustrationen, Diagramme
• Michaeli, Julia: Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price / Julia Caroline Michaeli, Thomas Michaeli, Dario Trapani, Sebastian Albers, Dominik Dannehl, Rachel W… , November 2024. - 12 S.
  In: Breast cancer, ISSN 1880-4233. 31(2024), 6 vom: Nov., Seite 1144-1155
  DOI: 10.1007/s12282-024-01634-x
• Michaeli, Daniel: Clinical trial design and treatment effects : a meta-analysis of randomised controlled and single-arm trials supporting 437 FDA approvals of cancer drugs and indications / Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli, September 20, 2024. - 9 S.
  In: BMJ evidence-based medicine, ISSN 2515-4478. 29(2024), 5 vom: Sept., Seite 333-341
  DOI: 10.1136/bmjebm-2023-112544
• Michaeli, Daniel: Breakthrough therapy cancer drugs and indications with FDA approval : development time, innovation, trials, clinical benefit, epidemiology, and price / Daniel Tobias Michaeli, MSc, MSc, and Thomas Michaeli, MD, MSc, MSc, May 2024. - 9 S. : Illustrationen
  In: Journal of the National Comprehensive Cancer Network, ISSN 1540-1413. 22(2024), 4, Seite 1-9
  DOI: 10.6004/jnccn.2023.7110
• Michaeli, Daniel: Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention / vorgelegt von Daniel Tobias Michaeli ; Referent: Priv.-Doz. Dr. med. Tobias Boch. -
  Heidelberg, 26 Nov. 2024. - 1 Online-Ressource (98 Seiten) : Illustrationen, Diagramme
  DOI: 10.11588/heidok.00035637
• Michaeli, Christoph T.: Partial orphan cancer drugs : US food and drug administration approval, clinical benefit, trials, epidemiology, price, beneficiaries, and spending / Thomas Michaeli, Daniel Tobias Michaeli, 18 January 2024. - 9 S.
  In: Value in health, ISSN 1524-4733. 27(2024), 4, Seite 449-457
  DOI: 10.1016/j.jval.2024.01.002
• Michaeli, Daniel: Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs / Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli, September 2024. - 13 S. : Illustrationen
  In: Targeted oncology, ISSN 1776-260X. 19(2024), 5 vom: Sept., Seite 797-809
  DOI: 10.1007/s11523-024-01081-w
• Michaeli, Daniel: Special FDA designations for drug development : orphan, fast track, accelerated approval, priority review, and breakthrough therapy / Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Tobias Boch, Julia Caroline Michaeli, 2024. - 19 S. : Illustrationen
  In: The European journal of health economics, ISSN 1618-7601. 25(2024), 6 vom: Aug., Seite 979-997
  DOI: 10.1007/s10198-023-01639-x
• Michaeli, Daniel: Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations / Daniel Tobias Michaeli, MSc, MSc, BSc, Thomas Michaeli, MD, MSc, MSc, BSc, Sebastian Albers , MD, Ju… , February 2024. - 14 S.
  In: Journal of the National Cancer Institute, ISSN 1460-2105. 116(2024), 2 vom: Feb., Seite 216-229
  DOI: 10.1093/jnci/djad212
• Michaeli, Daniel: Launch and post-launch prices of injectable cancer drugs in the US : clinical benefit, innovation, epidemiology, and competition / Daniel Tobias Michaeli, Thomas Michaeli, 2024. - 15 S. : Illustrationen
  In: PharmacoEconomics, ISSN 1179-2027. 42(2024), 1, Seite 117-131
  DOI: 10.1007/s40273-023-01320-4
• Michaeli, Julia: Gene regulation for inflammation and inflammation resolution differs between umbilical arterial and venous endothelial cells / Julia Caroline Michaeli, Sebastian Albers, Carolina de la Torre, Yannick Schreiner, Sara Faust, Thom… , 27 September 2023. - 11 S. : Illustrationen
  In: Scientific reports, ISSN 2045-2322. 13(2023), Artikel-ID 16159, Seite 1-11
  DOI: 10.1038/s41598-023-43142-6
• Michaeli, Daniel: Cost-effectiveness of lipid-lowering therapies for cardiovascular prevention in Germany / Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli, August 2023. - 12 S.
  In: Cardiovascular drugs and therapy, ISSN 1573-7241. 37(2023), 4 vom: Aug., Seite 683-694
  DOI: 10.1007/s10557-021-07310-y
• Michaeli, Daniel: Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention : leading article / Daniel Tobias Michaeli, Julia Caroline Michaeli, Sebastian Albers, Tobias Boch & Thomas Michaeli, September 2023. - 19 S. : Illustrationen
  In: American journal of cardiovascular drugs, ISSN 1179-187X. 23(2023), 5 vom: Sept., Seite 477-495
  DOI: 10.1007/s40256-023-00594-5
• Michaeli, Daniel: Cancer drug prices in the United States : efficacy, innovation, clinical trial evidence, and epidemiology / Daniel Tobias Michaeli, MSc, Thomas Michaeli, MD, MSc, November 2023. - 11 S.
  In: Value in health, ISSN 1524-4733. 26(2023), 11 vom: Nov., Seite 1590-1600
  DOI: 10.1016/j.jval.2023.06.020
• Michaeli, Daniel: Advances in cancer therapy : clinical benefit of new cancer drugs$deditorial / Daniel Tobias Michaeli, Julia Caroline Michaeli, Thomas Michaeli, June 19, 2023. - 3 S.
  In: Aging, ISSN 1945-4589. 15(2023), 12, Seite 5232-5234
  DOI: 10.18632/aging.204839
• Michaeli, Christoph T.: FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications : cross sectional analysis / Thomas Michaeli, Hendrik Jürges, Daniel Tobias Michaeli, 09 May 2023. - 12 S.
  In: The BMJ, ISSN 1756-1833. 381(2023), Artikel-ID e073242, Seite 1-12
  DOI: 10.1136/bmj-2022-073242
• Mills, Mackenzie: Launch sequencing of pharmaceuticals with multiple therapeutic indications : evidence from seven countries / Mackenzie Mills, Daniel Michaeli, Aurelio Miracolo and Panos Kanavos, 13 February 2023. - 17 S.
  In: BMC health services research, ISSN 1472-6963. 23(2023), Artikel-ID 150, Seite 1-17
  DOI: 10.1186/s12913-023-09095-2
• Michaeli, Daniel: Germany's healthcare system : funding, resource allocation, provider payment, efficiency, and access / Daniel Tobias Michaeli, Hasan Yagmur, Thomas Michaeli. -
  [S.l.]: SSRN, April 1, 2022. - 1 Online-Ressource (14 p)
  DOI: 10.2139/ssrn.4072939
• Michaeli, Daniel: Valuation and returns of drug development companies : lessons for bioentrepreneurs and investors / Daniel Tobias Michaeli, Hasan Basri Yagmur, Timur Achmadeev, Thomas Michaeli, 11. January 2022. - 10 S.
  In: Therapeutic innovation & regulatory science, ISSN 2168-4804. 56(2022), 2 vom: März, Seite 313-322
  DOI: 10.1007/s43441-021-00364-y
• Michaeli, Daniel: Cost-effectiveness of bivalent, quadrivalent, and nonavalent HPV vaccination in South Africa / Daniel Tobias Michaeli, Sophia Stoycheva, Simon Mashudu Marcus, Wenjia Zhang, Julia Caroline Michael… , 16 March 2022. - 11 S.
  In: Clinical drug investigation, ISSN 1179-1918. 42(2022), 4 vom: Apr., Seite 333-343
  DOI: 10.1007/s40261-022-01138-6
• Michaeli, Julia: Socio-economic burden of disease: survivorship costs for renal cell carcinoma / Julia Caroline Michaeli, Daniel Tobias Michaeli, Tobias Boch, Sebastian Albers, Thomas Michaeli, May 2022. - 11 S.
  In: European journal of cancer care, ISSN 1365-2354. 31(2022), 3 vom: Mai, Artikel-ID e13569, Seite 1-11
  DOI: 10.1111/ecc.13569
• Michaeli, Daniel: Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA : phase III studies / Daniel Tobias Michaeli, Mackenzie Mills, Thomas Michaeli, Aurelio Miracolo, Panos Kanavos, 7 April 2022. - 12 S.
  In: Investigational new drugs, ISSN 1573-0646. 40(2022), 4 vom: Aug., Seite 798-809
  DOI: 10.1007/s10637-022-01227-5
• Michaeli, Daniel: Cost-effectiveness of icosapent ethyl, evolocumab, alirocumab, ezetimibe, or fenofibrate in combination with dtatins compared to statin monotherapy / Daniel Tobias Michaeli, Julia Caroline Michaeli, Tobias Boch, Thomas Michaeli, 11 July 2022. - 14 S.
  In: Clinical drug investigation, ISSN 1179-1918. 42(2022), 8 vom: Aug., Seite 643-656
  DOI: 10.1007/s40261-022-01173-3
• Michaeli, Daniel: Value and price of multi-indication cancer drugs in the USA, Germany, France, England, Canada, Australia, and Scotland / Daniel Tobias Michaeli, Mackenzie Mills, Panos Kanavos, 11 July 2022. - 12 S.
  In: Applied health economics and health policy, ISSN 1179-1896. 20(2022), 5 vom: Sept., Seite 757-768
  DOI: 10.1007/s40258-022-00737-w
• Michaeli, Daniel: Overall survival, progression-free survival, and tumor response benefit supporting initial US Food and Drug Administration approval and indication extension of new cancer drugs, 2003-2021 / Daniel Tobias Michaeli, and Thomas Michaeli, August 3, 2022. - 13 S.
  In: Journal of clinical oncology, ISSN 1527-7755. 40(2022), 35, Seite 4095-4106
  DOI: 10.1200/JCO.22.00535
• Michaeli, Daniel: Value drivers of development stage biopharma companies / Daniel Tobias Michaeli, Hasan Basri Yagmur, Timur Achmadeev, Thomas Michaeli, 17 January 2022. - 10 S.
  In: The European journal of health economics, ISSN 1618-7601. 23(2022), 8 vom: Nov., Seite 1287-1296
  DOI: 10.1007/s10198-021-01427-5
• Michaeli, Christoph T.: Prostate cancer follow-up costs in Germany from 2000 to 2015 / Thomas Michaeli, Daniel Michaeli, 2022. - 9 S.
  In: Journal of cancer survivorship, ISSN 1932-2267. 16(2022), 1, Seite 86-94
  DOI: 10.1007/s11764-021-01006-w
• Michaeli, Christoph T.: Testicular cancer follow-up costs in Germany from 2000 to 2015 / Thomas Michaeli, Julia Michaeli, Daniel Michaeli, 22 April 2021. - 10 S.
  In: Journal of cancer research and clinical oncology, ISSN 1432-1335. 147(2021), 8, Seite 2249-2258
  DOI: 10.1007/s00432-021-03643-1

IDs

GND:	1277183244

Links

Michaeli, Daniel in ...

• Deutsche Nationalbibliothek (DNB)
• Virtual International Authority File (VIAF)

Export Publikationsliste

• RIS (Endnote)
• BibTeX
• RDF
• MODS
• P°NK (ExIni)

heiBIB

Bei fehlerhaften oder unvollständigen Angaben wenden Sie sich bitte an biblio@ub.uni-heidelberg.de.

Informationen zu heiBIB (inkl. Einbettung der Publikationslisten in eigene WWW-Seiten).